Orciprenaline


Full Prescribing Info
Dosage/Direction for Use

Oral
Chronic management of reversible airways obstruction
Adult: As sulfate: 20 mg 3 or 4 times daily.
Child: As sulfate: Up to 1 yr: 5-10 mg tid; 1-3 yr: 5-10 mg 4 times daily; 3-12 yr: 40-60 mg daily in divided doses.

Oral

Bradycardia
Adult: As sulfate: Up to 240 mg daily in divided doses.

Inhalation

Acute bronchospasm
Adult: As sulfate: Metered-dose inhaler releasing 750 mcg per inhalation: 1 or 2 inhalations; repeat if necessary. Max: Up to 12 inhalations in 24 hr. As 5% soln from a hand nebuliser: 10 inhalations. With a nebulising device e.g. intermittent positive-pressure breathing (IPPB) apparatus: 0.2-0.3 ml of a 5% solution diluted up to 2.5 ml physiological saline, administered not more often than every 4 hr.
Child: As sulfate: Metered-dose inhaler: >12 yr: 1 or 2 inhalations (750 mcg); repeat if necessary after not <3 hr. Max in 24 hr: <6 yr: Up to 4 inhalations; 6-12 yr: Up to 8 inhalations; >12 yr: Up to 12 inhalations. Nebuliser: Infants and children: 0.01-0.02 ml of 5% solution; min dose: 0.1 ml; max dose: 0.3 ml diluted in 2-3 ml normal saline every 4-6 hr or more frequently if necessary.

Intravenous

Bradycardia
Adult: As sulfate: 250-500 mcg by slow IV inj.
Administration
May be taken with or without food.
Contraindications
Cardiac arrhythmias associated with tachycardia.
Special Precautions
CV disease (e.g. arrhythmia, hypertension, CHF), DM, glaucoma, hyperthyroidism, hypokalaemia, seizure disorders. Pregnancy and lactation.
Adverse Reactions
Tachycardia, nervousness, increased serum glucose, increased potassium levels, tremor, palpitation, headache, dizziness, insomnia, nausea, vomiting, bad taste, heartburn, xerostomia, trembling, muscle cramps, weakness, coughing, pharyngitis, increased diaphoresis, paradoxical bronchospasm, hypertension, chest pain, angina, drowsiness, diarrhoea, taste change.
Overdosage
Symptoms: Tachycardia, tremor, hypertension, angina, seizures, hypokalaemia. Treatment: Immediate discontinuation and symptomatic and supportive therapies. Cautious use of β-blockers may be considered in severe cases.
Drug Interactions
Effects may be antagonised by β-blockers e.g. propranolol. Duration of bronchodilation may be increased with inhaled ipratropium. Increased adverse effects with MAOIs, TCAs, sympathomimetics.
Potentially Fatal: Increased risk of malignant arrhythmias with halothane.
Action
Orciprenaline is a direct acting sympathomimetic with predominantly β2-adrenoceptor stimulant activity. It has minimal effect on heart rate.
Onset: Inhaler: Within 1 min. Nebuliser: 5-30 min. Oral: 15 min.
Duration: Up to 6 hr (inhalation).
Absorption: Absorbed from the GI tract (oral).
Metabolism: Hepatic; undergoes extensive first-pass metabolism.
Excretion: Via urine (mainly as metabolites).
Storage
Inhalation: Metered-dose inhaler: Store at 15-25°C. Nebuliser: Store below 25°C. Protect from light. Oral: Store in tight, light-resistant containers at 15-30°C.
ATC Classification
R03AB03 - orciprenaline ; Belongs to the class of adrenergic inhalants, non-selective beta-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
R03CB03 - orciprenaline ; Belongs to the class of adrenergics for systemic use, non-selective beta-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
Disclaimer: This information is independently developed by CIMS based on orciprenaline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in